These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The first reported case of a patient with pancreatic cancer treated with cone beam computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR). Kim M; Schiff JP; Price A; Laugeman E; Samson PP; Kim H; Badiyan SN; Henke LE Radiat Oncol; 2022 Sep; 17(1):157. PubMed ID: 36100866 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Henke L; Kashani R; Robinson C; Curcuru A; DeWees T; Bradley J; Green O; Michalski J; Mutic S; Parikh P; Olsen J Radiother Oncol; 2018 Mar; 126(3):519-526. PubMed ID: 29277446 [TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy. Tyran M; Jiang N; Cao M; Raldow A; Lamb JM; Low D; Luterstein E; Steinberg ML; Lee P Radiother Oncol; 2018 Nov; 129(2):319-325. PubMed ID: 30174107 [TBL] [Abstract][Full Text] [Related]
5. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial. Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270 [TBL] [Abstract][Full Text] [Related]
6. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers. Padgett KR; Simpson G; Asher D; Portelance L; Bossart E; Dogan N Phys Med; 2020 Sep; 77():54-63. PubMed ID: 32781388 [TBL] [Abstract][Full Text] [Related]
7. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. Bohoudi O; Bruynzeel AME; Senan S; Cuijpers JP; Slotman BJ; Lagerwaard FJ; Palacios MA Radiother Oncol; 2017 Dec; 125(3):439-444. PubMed ID: 28811038 [TBL] [Abstract][Full Text] [Related]
8. Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience. Garcia Schüler HI; Pavic M; Mayinger M; Weitkamp N; Chamberlain M; Reiner C; Linsenmeier C; Balermpas P; Krayenbühl J; Guckenberger M; Baumgartl M; Wilke L; Tanadini-Lang S; Andratschke N Radiat Oncol; 2021 Nov; 16(1):217. PubMed ID: 34775998 [TBL] [Abstract][Full Text] [Related]
9. Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer. El-Bared N; Portelance L; Spieler BO; Kwon D; Padgett KR; Brown KM; Mellon EA Pract Radiat Oncol; 2019 Jan; 9(1):e46-e54. PubMed ID: 30149192 [TBL] [Abstract][Full Text] [Related]
10. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC). Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490 [TBL] [Abstract][Full Text] [Related]
11. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. Henke L; Kashani R; Yang D; Zhao T; Green O; Olsen L; Rodriguez V; Wooten HO; Li HH; Hu Y; Bradley J; Robinson C; Parikh P; Michalski J; Mutic S; Olsen JR Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1078-1086. PubMed ID: 27742541 [TBL] [Abstract][Full Text] [Related]
12. Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors. Padgett KR; Simpson GN; Llorente R; Samuels MA; Dogan N Cureus; 2018 Apr; 10(4):e2423. PubMed ID: 29872603 [TBL] [Abstract][Full Text] [Related]
13. Dosimetric predictors of acute and late gastrointestinal toxicities in stereotactic online adaptive magnetic resonance-guided radiotherapy (SMART) for locally advanced pancreatic adenocarcinoma. D'Souza A; Stowe HB; Green OL; Schiff J; Hugo GD; Ginn J; Maraghechi B; Kang KH; Kim H; Badiyan SN; Samson P; Robinson CG; Price A; Henke LE Radiother Oncol; 2024 Nov; 200():110473. PubMed ID: 39137832 [TBL] [Abstract][Full Text] [Related]
14. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321 [TBL] [Abstract][Full Text] [Related]
15. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Parikh PJ; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Pfeffer MR; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Chuong MD Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):799-808. PubMed ID: 37210048 [TBL] [Abstract][Full Text] [Related]
16. Technical Assessment of an Automated Treatment Planning on Dose Escalation of Pancreas Stereotactic Body Radiotherapy. Wang S; Zheng D; Lin C; Lei Y; Verma V; Smith A; Ma R; Enke CA; Zhou S Technol Cancer Res Treat; 2019 Jan; 18():1533033819851520. PubMed ID: 31195891 [TBL] [Abstract][Full Text] [Related]
17. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study. Weisz Ejlsmark M; Bahij R; Schytte T; Rønn Hansen C; Bertelsen A; Mahmood F; Bau Mortensen M; Detlefsen S; Weber B; Bernchou U; Pfeiffer P Radiother Oncol; 2024 Aug; 197():110347. PubMed ID: 38815694 [TBL] [Abstract][Full Text] [Related]
18. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study. Chuong MD; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Raphael Pfeffer M; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Jitendra Parikh P Radiother Oncol; 2024 Feb; 191():110064. PubMed ID: 38135187 [TBL] [Abstract][Full Text] [Related]
19. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK. Nugent K; Mukherjee S; Teoh S; George B; Martin A; Gaya A; Aznar-Garcia L; Chu K; Robinson M; Maughan T; Good J Clin Oncol (R Coll Radiol); 2024 Sep; 36(9):576-584. PubMed ID: 38902119 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions. Bryant JM; Weygand J; Keit E; Cruz-Chamorro R; Sandoval ML; Oraiqat IM; Andreozzi J; Redler G; Latifi K; Feygelman V; Rosenberg SA Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]